Transplantation in adult patients with Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis: yes or no?

噬血细胞性淋巴组织细胞增多症 美罗华 医学 移植 胃肠病学 造血干细胞移植 免疫学 淋巴瘤 内科学 疾病
作者
Shuyan Yao,Cui Feng,Lingbo He,Menghan Liu,Zhengjie Hua,Heshan Zou,Yingxin Zhu,Zhao Wang,Yini Wang
出处
期刊:Blood [Elsevier BV]
卷期号:144 (20): 2107-2120 被引量:15
标识
DOI:10.1182/blood.2023023287
摘要

Abstract Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by aberrant immunological activity with a dismal prognosis. Epstein-Barr virus (EBV)–associated HLH (EBV-HLH) is the most common type among adults. Patients with EBV infection to B cells could benefit from rituximab, whereas lethal outcomes may occur in patients with EBV infection to T cells, nature killer cells, or multilineages. The necessity of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with EBV-HLH remains controversial. A total of 356 adult patients with EBV-HLH entered this study. Eighty-eight received HSCT under medical recommendation. Four received salvage HSCT. The 5-year overall survival (OS) rate for patients who underwent HSCT was 48.7% (vs 16.2% in patients who did not undergo transplantation; P < .001). There was no difference in OS between patients who received transplantation at first complete response (CR1) and those at first partial response (PR1) nor between patients at CR1 and CR2. Patients who received transplantation at PR2 had inferior survival. The rate of reaching CR2 was significantly higher in patients with CR1 than PR1 (P = .014). Higher soluble CD25 levels, higher EBV-DNA loads in plasma after HSCT, poorer remission status, more advanced acute graft-versus-host disease (GVHD), and the absence of localized chronic GVHD were associated with inferior prognosis (P < .05). HSCT improved the survival of adult EBV-HLH significantly. For patients who achieved PR after initial treatment, HSCT was recommended. A wait-and-see strategy could be adopted for patients who achieved CR after initial treatment but with the risk of failing to achieve CR2.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Present发布了新的文献求助30
1秒前
1秒前
指尖发布了新的文献求助10
1秒前
Lily发布了新的文献求助10
1秒前
科研通AI6.2的应助被什米采纳,获得10
1秒前
深情安青的应助被友好的诗筠采纳,获得10
1秒前
2秒前
2秒前
Cheryl发布了新的文献求助10
3秒前
li完成签到,获得积分10
3秒前
ddddd完成签到,获得积分10
3秒前
3秒前
5秒前
5秒前
春申君发布了新的文献求助10
5秒前
ding的应助被天真的日记本采纳,获得10
6秒前
6秒前
7秒前
七月流火的应助被rapamycin采纳,获得10
7秒前
舒适雪糕完成签到,获得积分10
7秒前
深情安青的应助被cc采纳,获得10
7秒前
7秒前
哎哟可爱完成签到,获得积分10
7秒前
8秒前
bkagyin的应助被大意的面包采纳,获得10
8秒前
沈吃俭用完成签到,获得积分10
8秒前
ayzx完成签到,获得积分10
8秒前
8秒前
做好人难完成签到,获得积分10
8秒前
陈二坎发布了新的文献求助10
8秒前
8秒前
林木木发布了新的文献求助30
8秒前
Maestro_S的应助被欢--采纳,获得10
9秒前
kou发布了新的文献求助10
9秒前
9秒前
灰灰完成签到,获得积分10
10秒前
demon1发布了新的文献求助10
10秒前
改善完成签到,获得积分10
10秒前
molihuakai的应助被如意巨人采纳,获得10
10秒前
拂晓完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124